Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Oncology Institute (TOI) Accumulated Expenses (2020 - 2025)

Oncology Institute (TOI) has disclosed Accumulated Expenses for 6 consecutive years, with $22.8 million as the latest value for Q3 2025.

  • For the quarter ending Q3 2025, Accumulated Expenses rose 47.61% year-over-year to $22.8 million, compared with a TTM value of $22.8 million through Sep 2025, up 47.61%, and an annual FY2024 reading of $21.1 million, up 50.71% over the prior year.
  • Accumulated Expenses was $22.8 million for Q3 2025 at Oncology Institute, roughly flat from $22.9 million in the prior quarter.
  • Across five years, Accumulated Expenses topped out at $23.4 million in Q1 2025 and bottomed at $80000.0 in Q1 2021.
  • Average Accumulated Expenses over 5 years is $14.3 million, with a median of $14.5 million recorded in 2022.
  • The sharpest move saw Accumulated Expenses soared 18045.0% in 2022, then dropped 21.21% in 2023.
  • Year by year, Accumulated Expenses stood at $13.9 million in 2021, then increased by 4.82% to $14.6 million in 2022, then fell by 4.1% to $14.0 million in 2023, then skyrocketed by 50.71% to $21.1 million in 2024, then increased by 8.02% to $22.8 million in 2025.
  • Business Quant data shows Accumulated Expenses for TOI at $22.8 million in Q3 2025, $22.9 million in Q2 2025, and $23.4 million in Q1 2025.